Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $11

Author: Benzinga Newsdesk | May 11, 2023 05:27am
Chardan Capital analyst Geulah Livshits maintains Achilles Therapeutics (NASDAQ:ACHL) with a Buy and lowers the price target from $12 to $11.

Posted In: ACHL